Skip to main content
Eli LillyPartnership

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

Source: Autobound Signal API · 114 signals tracked for Eli Lilly · updated

Get Eli Lilly's live signals in Claude or ChatGPT, or by API

AskWhat changed at Eli Lilly this week? Use Autobound signals for lilly.com.

What happened

Eli Lilly and Company partnered with Hims & Hers Health, Inc. to expand patient access to FDA-approved obesity treatments Zepbound and Foundayo through the Hims & Hers telehealth platform.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Hims & Hers Health, Inc. (NYSE: HIMS ) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform. The agreement brings together Lilly's obesity medicines and Hims & Hers' consumer platform. Patients can complete a consultation, receive a prescription if their provider determines it is appropriate, and have an FDA-approved Lilly medicine shipped directly to their home, all in one seamless experience. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound. "At Lilly, we are always looking for new ways to help more people get the medicines they need, and that means meeting patients where they already are," said Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities, Eli Lilly and Company. "Millions of people turn to Hims & Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly...

Keep reading with a free account

The rest of this article, and every signal for Eli Lilly, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership

What this signalsA new partnership often opens integration and co-selling work.

Takes effect
Nov 6, 2026
Location
Indianapolis, Indiana, United States

Companies

  • Hims & Hers Health, Inc.Partnerhimsandhershealth.com

More partnership signals at other companies

The full record

From the Signal API record

Details

Ticker
NYSE:LLY

Extraction

Confidence
95%
Detected
Nov 6, 2026
signal_type
news
signal_subtype
partners_with

Use this data

Get every partnership signal for Eli Lilly and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Eli Lilly this week?”

  2. Send it to your own tools

    The Signal API returns partnership signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/51d7e4b9-9214-881c-0326-09afefb188cf returns this record as JSON. POST /v1/companies/enrich returns every signal for lilly.com.

{
  "signal_id": "51d7e4b9-9214-881c-0326-09afefb188cf",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-11-06T11:47:00+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/lilly-and-hims--hers-expand-access-to-fda-approved-lilly-medicines-302931979.html",
    "title": "Lilly and Hims & Hers expand access to FDA-approved Lilly medicines",
    "ticker": "NYSE:LLY",
    "excerpt": "Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS , Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Hims & Hers Health, Inc. (NYSE: HIMS ) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform. The agreement brings together Lilly's obesity medicines and Hims & Hers' consumer platform. Patients can complete a consultation, receive a prescription if their provider determines it is appropriate, and have an FDA-approved Lilly medicine shipped directly to their home, all in one seamless experience. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound. \"At Lilly, we are always looking for new ways to help more people get the medicines they need, and that means meeting patients where they already are,\" said Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities, Eli Lilly and Company. \"Millions of people turn to Hims & Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly...",
    "summary": "Eli Lilly and Company partnered with Hims & Hers Health, Inc. to expand patient access to FDA-approved obesity treatments Zepbound and Foundayo through the Hims & Hers telehealth platform.",
    "location": "Indianapolis, Indiana, United States",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS270365/ELI-LILLY-AND-COMPANY-LOGO.jpg?id=OA3061937&p=facebook",
    "confidence": 0.95,
    "published_at": "2026-11-06T11:47:00Z",
    "location_data": [
      {
        "city": "Indianapolis",
        "state": "Indiana",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-06",
    "article_sentence": "Eli Lilly and Company (NYSE: LLY ) and Hims & Hers Health, Inc. (NYSE: HIMS ) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron).",
    "related_company_name": "Hims & Hers Health, Inc.",
    "related_company_domain": "himsandhershealth.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.